This section of the programme lists abstracts and e-posters.
Drug-drug interaction between emtricitabine/tenofovir alafenamide (FTC/TAF)-based PrEP and feminizing hormones in transgender women: peripheral blood mononuclear cells and urine analysis from the iFACT3 study | Oral abstract session with live Q&A | HIV prevention research |
Persistent accelerated epigenetic aging is associated with altered neuroimaging and immune biomarkers in a longitudinal cohort of vertically-acquired HIV-positive adolescents | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in infants, children and adolescents |
Prior M184V/I and multiple prior virological failures have no impact on the efficacy of switching HIV+ adults to DTG/3TC through 96Wks in SOLAR-3D | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
In vivo genome engineering of human T cells results in ART-free control of HIV-1 in humanized mice | Oral abstract session with live Q&A | Novel treatment and prevention strategies |
Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
Protective efficacy of intranasal vaccination with a Sendai virus vector expressing a spike antigen against SARS-CoV-2 infection in mice | Oral abstract session with live Q&A | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
Reporting, prevention and response of gender based violence against men who have sex with men in Taraba State, Nigeria | Oral abstract session with live Q&A | Social and behavioural aspects and approaches to HIV |
COVID-19 vaccine effectiveness by HIV status and injection drug use history | Oral abstract session with live Q&A | Epidemiology of COVID-19 |
Gut memory CD4+ T cells from people with HIV on suppressive ART express high levels of intracellular HIV sensors | Oral abstract session with live Q&A | HIV pathogenesis |
Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |